The provided text appears to be an excerpt from a Form 10-Q report filed by Eli Lilly and Company with the U.S. Securities and Exchange Commission. This report summarizes the company's financial performance for the quarter ending June 30, 2024. The report includes consolidated condensed statements of operations, comprehensive income, balance sheets, shareholders' equity, and cash flows, as well as a management's discussion and analysis of results of operations and financial condition. It also covers key accounting estimates, disclosures about market risk, and information on legal proceedings, risk factors, and collaborations.